Supplemental Annuity Collective Trust (SACT) of New Jersey’s Viking Therapeutics VKTX Stock Holding History

Supplemental Annuity Collective Trust (SACT) of New Jersey’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-11,300	Closed	-$398K	–	365
2025 Q4	$398K	Hold	11,300	–	–	0.1%	174
2025 Q3	$297K	Buy	+11,300	New	+$337K	0.08%	191
2025 Q1	–	Sell	-7,000	Closed	-$282K	–	213
2024 Q4	$282K	Hold	7,000	–	–	0.08%	189
2024 Q3	$443K	Hold	7,000	–	–	0.13%	165
2024 Q2	$371K	Buy	+7,000	New	+$459K	0.11%	175

Other funds holding VKTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Supplemental Annuity Collective Trust (SACT) of New Jersey's VKTX Position: Q1 2026 in Review

Supplemental Annuity Collective Trust (SACT) of New Jersey sold out of Viking Therapeutics (VKTX) in Q1 2026, closing a stake of 11,300 shares — an estimated $398K sold.

Supplemental Annuity Collective Trust (SACT) of New Jersey first reported a position in VKTX in Q2 2024 and held it in 5 quarters. The position peaked at $443K in Q3 2024. 412 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

Supplemental Annuity Collective Trust (SACT) of New Jersey reported no remaining Viking Therapeutics position as of Q1 2026 after selling out during the quarter.
Supplemental Annuity Collective Trust (SACT) of New Jersey sold 11,300 Viking Therapeutics shares in Q1 2026, an estimated $398K.
Supplemental Annuity Collective Trust (SACT) of New Jersey first reported a position in Viking Therapeutics in Q2 2024 and held it in 5 quarters.
Supplemental Annuity Collective Trust (SACT) of New Jersey's Viking Therapeutics position peaked at $443K in Q3 2024.
412 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Supplemental Annuity Collective Trust (SACT) of New Jersey's 13F filing for Q1 2026, filed 1 May 2026.